Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 105 | 2023 | 20822 | 2.080 |
Why?
|
Antineoplastic Agents, Hormonal | 19 | 2022 | 1524 | 1.560 |
Why?
|
Neoplasms, Hormone-Dependent | 7 | 2014 | 415 | 1.040 |
Why?
|
Aromatase Inhibitors | 9 | 2019 | 491 | 0.970 |
Why?
|
Tamoxifen | 10 | 2019 | 981 | 0.780 |
Why?
|
Receptor, erbB-2 | 20 | 2023 | 2416 | 0.730 |
Why?
|
Estradiol | 9 | 2019 | 2020 | 0.590 |
Why?
|
Mastectomy | 15 | 2022 | 1793 | 0.510 |
Why?
|
Selective Estrogen Receptor Modulators | 2 | 2006 | 129 | 0.510 |
Why?
|
Estrogen Antagonists | 6 | 2005 | 152 | 0.490 |
Why?
|
Receptors, Progesterone | 8 | 2021 | 1097 | 0.460 |
Why?
|
Estrogen Receptor Modulators | 2 | 2011 | 61 | 0.450 |
Why?
|
Receptors, Estrogen | 14 | 2021 | 2187 | 0.440 |
Why?
|
Carcinoma, Lobular | 2 | 2008 | 484 | 0.430 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 36 | 2020 | 11524 | 0.390 |
Why?
|
Anxiety | 9 | 2022 | 4297 | 0.370 |
Why?
|
Nitriles | 5 | 2008 | 956 | 0.350 |
Why?
|
Androstadienes | 3 | 2008 | 346 | 0.350 |
Why?
|
Mastectomy, Segmental | 11 | 2022 | 956 | 0.340 |
Why?
|
Triazoles | 5 | 2008 | 911 | 0.340 |
Why?
|
Sexual Partners | 3 | 2022 | 730 | 0.320 |
Why?
|
Pregnancy Complications, Neoplastic | 2 | 2020 | 255 | 0.310 |
Why?
|
BRCA2 Protein | 4 | 2022 | 794 | 0.300 |
Why?
|
Antineoplastic Agents | 18 | 2021 | 13695 | 0.290 |
Why?
|
Neoplasm Staging | 30 | 2022 | 11031 | 0.280 |
Why?
|
BRCA1 Protein | 4 | 2022 | 1149 | 0.270 |
Why?
|
Female | 122 | 2023 | 380194 | 0.250 |
Why?
|
Chemotherapy, Adjuvant | 13 | 2022 | 3479 | 0.240 |
Why?
|
Estrogen Receptor alpha | 2 | 2021 | 577 | 0.240 |
Why?
|
Quinazolines | 6 | 2013 | 1356 | 0.230 |
Why?
|
Fluorouracil | 12 | 2014 | 1619 | 0.220 |
Why?
|
Prospective Studies | 31 | 2023 | 53288 | 0.210 |
Why?
|
Adult | 87 | 2023 | 214055 | 0.210 |
Why?
|
Fertility | 3 | 2022 | 781 | 0.210 |
Why?
|
Carcinoma | 3 | 2021 | 2375 | 0.200 |
Why?
|
Neoadjuvant Therapy | 3 | 2020 | 2728 | 0.190 |
Why?
|
Adaptation, Psychological | 2 | 2022 | 2576 | 0.190 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 3703 | 0.190 |
Why?
|
Cyclophosphamide | 15 | 2013 | 2242 | 0.190 |
Why?
|
Gene Expression | 1 | 2013 | 7799 | 0.180 |
Why?
|
Decision Making | 5 | 2019 | 3887 | 0.180 |
Why?
|
Quality of Life | 9 | 2022 | 12804 | 0.180 |
Why?
|
Humans | 135 | 2023 | 744343 | 0.180 |
Why?
|
Gene Expression Profiling | 4 | 2019 | 9438 | 0.160 |
Why?
|
Doxorubicin | 14 | 2013 | 2234 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 15 | 2022 | 9239 | 0.160 |
Why?
|
Social Support | 5 | 2022 | 2118 | 0.150 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2023 | 489 | 0.150 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2019 | 187 | 0.150 |
Why?
|
Combined Modality Therapy | 28 | 2022 | 8642 | 0.150 |
Why?
|
Carcinoma in Situ | 1 | 2022 | 806 | 0.140 |
Why?
|
Body Image | 3 | 2020 | 610 | 0.140 |
Why?
|
Breast | 3 | 2022 | 1969 | 0.140 |
Why?
|
Parenting | 1 | 2022 | 679 | 0.130 |
Why?
|
Attitude | 1 | 2020 | 776 | 0.130 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2019 | 360 | 0.130 |
Why?
|
Young Adult | 20 | 2022 | 56430 | 0.130 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 949 | 0.130 |
Why?
|
Patient Participation | 2 | 2015 | 1457 | 0.120 |
Why?
|
Neoplasm Metastasis | 13 | 2018 | 4851 | 0.120 |
Why?
|
Reproductive History | 1 | 2015 | 209 | 0.120 |
Why?
|
Biopsy | 5 | 2022 | 6756 | 0.120 |
Why?
|
Clinical Trials as Topic | 7 | 2014 | 7913 | 0.110 |
Why?
|
Mammary Glands, Human | 1 | 2014 | 199 | 0.110 |
Why?
|
Middle Aged | 58 | 2022 | 213383 | 0.110 |
Why?
|
Cisplatin | 6 | 2015 | 1662 | 0.110 |
Why?
|
Adult Stem Cells | 1 | 2014 | 216 | 0.110 |
Why?
|
Employment | 1 | 2019 | 1132 | 0.110 |
Why?
|
Depression | 4 | 2020 | 7766 | 0.110 |
Why?
|
Amenorrhea | 2 | 2014 | 485 | 0.110 |
Why?
|
Radiotherapy | 3 | 2017 | 1533 | 0.110 |
Why?
|
Spouses | 1 | 2015 | 286 | 0.110 |
Why?
|
Methotrexate | 8 | 2005 | 1727 | 0.100 |
Why?
|
Carboplatin | 1 | 2015 | 801 | 0.100 |
Why?
|
Mutation | 8 | 2023 | 29786 | 0.100 |
Why?
|
Tissue Donors | 1 | 2020 | 2240 | 0.100 |
Why?
|
Deglutition Disorders | 1 | 2017 | 605 | 0.100 |
Why?
|
Pyridines | 2 | 2020 | 2825 | 0.100 |
Why?
|
Breast Feeding | 1 | 2019 | 1338 | 0.100 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2014 | 640 | 0.090 |
Why?
|
Socioeconomic Factors | 6 | 2021 | 7785 | 0.090 |
Why?
|
Hodgkin Disease | 7 | 1996 | 1415 | 0.090 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2010 | 648 | 0.090 |
Why?
|
Radiation Injuries | 2 | 2017 | 1180 | 0.090 |
Why?
|
Deoxycytidine | 1 | 2014 | 826 | 0.090 |
Why?
|
Adolescent | 21 | 2022 | 85781 | 0.090 |
Why?
|
Prognosis | 17 | 2021 | 29063 | 0.090 |
Why?
|
Disease-Free Survival | 8 | 2019 | 6895 | 0.090 |
Why?
|
Treatment Outcome | 22 | 2021 | 63114 | 0.090 |
Why?
|
Lymphatic Metastasis | 6 | 2021 | 2924 | 0.080 |
Why?
|
Piperazines | 1 | 2019 | 2488 | 0.080 |
Why?
|
Aged | 39 | 2022 | 163280 | 0.080 |
Why?
|
Creatine Kinase | 1 | 1990 | 694 | 0.080 |
Why?
|
Age Factors | 7 | 2021 | 18370 | 0.080 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2011 | 629 | 0.080 |
Why?
|
Live Birth | 2 | 2023 | 512 | 0.080 |
Why?
|
Germ Cells | 2 | 2022 | 631 | 0.080 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1094 | 0.080 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 2727 | 0.080 |
Why?
|
Survivors | 3 | 2023 | 2291 | 0.080 |
Why?
|
Infertility, Female | 1 | 2014 | 787 | 0.080 |
Why?
|
Medication Adherence | 1 | 2019 | 2063 | 0.080 |
Why?
|
Interpersonal Relations | 1 | 2015 | 1425 | 0.070 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2011 | 841 | 0.070 |
Why?
|
Drug Administration Schedule | 4 | 2015 | 4933 | 0.070 |
Why?
|
Postmenopause | 6 | 2005 | 2461 | 0.070 |
Why?
|
Perception | 1 | 2013 | 1198 | 0.070 |
Why?
|
Pregnancy Outcome | 3 | 2023 | 2795 | 0.070 |
Why?
|
Troponin I | 1 | 2011 | 619 | 0.070 |
Why?
|
Genetic Testing | 2 | 2016 | 3444 | 0.070 |
Why?
|
Patient Satisfaction | 2 | 2021 | 3396 | 0.070 |
Why?
|
Multicenter Studies as Topic | 1 | 2011 | 1677 | 0.070 |
Why?
|
Paclitaxel | 5 | 2013 | 1708 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3309 | 0.060 |
Why?
|
Diagnosis-Related Groups | 1 | 1987 | 455 | 0.060 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2022 | 890 | 0.060 |
Why?
|
Filgrastim | 3 | 2010 | 133 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 2 | 2019 | 5535 | 0.060 |
Why?
|
Sexual Behavior | 1 | 2014 | 2057 | 0.060 |
Why?
|
Cohort Studies | 8 | 2020 | 40561 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7279 | 0.060 |
Why?
|
Time Factors | 9 | 2020 | 40075 | 0.060 |
Why?
|
Medical Oncology | 1 | 2015 | 2265 | 0.060 |
Why?
|
Taxoids | 1 | 2007 | 666 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2022 | 17446 | 0.060 |
Why?
|
Diarrhea | 1 | 2010 | 1348 | 0.060 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2020 | 4266 | 0.050 |
Why?
|
Aged, 80 and over | 10 | 2020 | 57776 | 0.050 |
Why?
|
Reticulocytes | 2 | 1974 | 290 | 0.050 |
Why?
|
Heterozygote | 2 | 2022 | 2804 | 0.050 |
Why?
|
Premenopause | 1 | 2006 | 1033 | 0.050 |
Why?
|
Parity | 2 | 2015 | 929 | 0.050 |
Why?
|
Lymphoma | 3 | 2017 | 1877 | 0.050 |
Why?
|
Hospitals, Teaching | 1 | 1987 | 1179 | 0.050 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 1990 | 1381 | 0.050 |
Why?
|
Pregnancy | 5 | 2023 | 29144 | 0.050 |
Why?
|
Ovary | 1 | 2006 | 981 | 0.050 |
Why?
|
Cross-Sectional Studies | 5 | 2022 | 25043 | 0.050 |
Why?
|
Axilla | 2 | 2021 | 595 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 3843 | 0.050 |
Why?
|
Feasibility Studies | 4 | 2019 | 5078 | 0.050 |
Why?
|
Erythropoietin | 1 | 2005 | 726 | 0.050 |
Why?
|
Antibodies, Monoclonal | 4 | 2011 | 9274 | 0.050 |
Why?
|
Genes, BRCA2 | 2 | 2015 | 618 | 0.050 |
Why?
|
Arm | 2 | 2021 | 589 | 0.050 |
Why?
|
Educational Status | 2 | 2019 | 2540 | 0.050 |
Why?
|
Leukemia, Lymphoid | 1 | 1980 | 315 | 0.050 |
Why?
|
Genes, BRCA1 | 2 | 2015 | 781 | 0.050 |
Why?
|
Neutropenia | 1 | 2005 | 895 | 0.050 |
Why?
|
Stroke Volume | 2 | 2011 | 5007 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2019 | 12261 | 0.040 |
Why?
|
Fear | 2 | 2021 | 1440 | 0.040 |
Why?
|
Medication Errors | 1 | 2006 | 798 | 0.040 |
Why?
|
Lung Diseases, Fungal | 1 | 1980 | 122 | 0.040 |
Why?
|
Vinblastine | 3 | 2013 | 502 | 0.040 |
Why?
|
Brain Neoplasms | 2 | 2013 | 8863 | 0.040 |
Why?
|
Furans | 1 | 2020 | 194 | 0.040 |
Why?
|
Ketones | 1 | 2020 | 188 | 0.040 |
Why?
|
C-Reactive Protein | 1 | 2011 | 3778 | 0.040 |
Why?
|
Polyethylene Glycols | 3 | 2010 | 1182 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2013 | 3923 | 0.040 |
Why?
|
Aspergillosis | 1 | 1980 | 235 | 0.040 |
Why?
|
Blood Donors | 1 | 2020 | 355 | 0.040 |
Why?
|
Risk Factors | 10 | 2021 | 72290 | 0.040 |
Why?
|
Academies and Institutes | 1 | 2020 | 317 | 0.040 |
Why?
|
Vaginal Diseases | 1 | 2019 | 102 | 0.040 |
Why?
|
Drug Hypersensitivity | 1 | 2007 | 884 | 0.040 |
Why?
|
Survival Rate | 10 | 2010 | 12788 | 0.040 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 402 | 0.040 |
Why?
|
Ovariectomy | 2 | 2019 | 661 | 0.040 |
Why?
|
Models, Genetic | 1 | 2008 | 3494 | 0.040 |
Why?
|
Pregnancy Rate | 1 | 2020 | 643 | 0.040 |
Why?
|
Mammaplasty | 2 | 2021 | 1204 | 0.040 |
Why?
|
Unemployment | 1 | 2019 | 214 | 0.040 |
Why?
|
Logistic Models | 3 | 2018 | 13408 | 0.040 |
Why?
|
Adjuvants, Immunologic | 1 | 2022 | 1000 | 0.040 |
Why?
|
Prevalence | 3 | 2020 | 15226 | 0.040 |
Why?
|
Anilides | 1 | 2020 | 408 | 0.040 |
Why?
|
Leuprolide | 1 | 2019 | 321 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2011 | 10943 | 0.040 |
Why?
|
Heartburn | 1 | 2017 | 68 | 0.040 |
Why?
|
Lactation | 1 | 2019 | 412 | 0.040 |
Why?
|
Genomics | 2 | 2023 | 5720 | 0.040 |
Why?
|
Hot Flashes | 1 | 2019 | 317 | 0.040 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2021 | 709 | 0.040 |
Why?
|
Heart Diseases | 1 | 2009 | 2788 | 0.040 |
Why?
|
Factor Analysis, Statistical | 1 | 2019 | 977 | 0.040 |
Why?
|
Hormones | 1 | 2020 | 889 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2021 | 1770 | 0.030 |
Why?
|
Anemia | 1 | 2005 | 1506 | 0.030 |
Why?
|
Lymph Node Excision | 2 | 2021 | 1261 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2011 | 9959 | 0.030 |
Why?
|
Mediastinum | 1 | 2017 | 267 | 0.030 |
Why?
|
Disease Progression | 4 | 2019 | 13284 | 0.030 |
Why?
|
Morbidity | 1 | 2021 | 1769 | 0.030 |
Why?
|
Infusions, Intra-Arterial | 5 | 1981 | 234 | 0.030 |
Why?
|
Anemia, Hypochromic | 1 | 1974 | 66 | 0.030 |
Why?
|
Actuarial Analysis | 5 | 1996 | 378 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12245 | 0.030 |
Why?
|
Keratin-14 | 1 | 2014 | 57 | 0.030 |
Why?
|
Keratin-18 | 1 | 2014 | 39 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2971 | 0.030 |
Why?
|
Age Distribution | 1 | 2020 | 2902 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2010 | 6622 | 0.030 |
Why?
|
Hepatic Artery | 5 | 1984 | 245 | 0.030 |
Why?
|
Follow-Up Studies | 13 | 2014 | 39050 | 0.030 |
Why?
|
Colorado | 1 | 2014 | 163 | 0.030 |
Why?
|
Radiotherapy Dosage | 7 | 1999 | 2879 | 0.030 |
Why?
|
Directive Counseling | 1 | 2015 | 166 | 0.030 |
Why?
|
Mastectomy, Radical | 1 | 1993 | 20 | 0.030 |
Why?
|
Mastectomy, Simple | 1 | 1993 | 24 | 0.030 |
Why?
|
Models, Psychological | 1 | 2018 | 811 | 0.030 |
Why?
|
Forecasting | 1 | 2003 | 2951 | 0.030 |
Why?
|
Spirituality | 1 | 2018 | 405 | 0.030 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2015 | 6038 | 0.030 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1101 | 0.030 |
Why?
|
Retrospective Studies | 11 | 2020 | 77449 | 0.030 |
Why?
|
Loss of Heterozygosity | 1 | 2015 | 684 | 0.030 |
Why?
|
Tissue and Organ Procurement | 1 | 2020 | 896 | 0.030 |
Why?
|
Neoplasms | 5 | 1990 | 21683 | 0.030 |
Why?
|
Floxuridine | 3 | 1981 | 49 | 0.030 |
Why?
|
Preoperative Period | 1 | 2014 | 549 | 0.030 |
Why?
|
Weight Gain | 1 | 2022 | 2292 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2007 | 5172 | 0.030 |
Why?
|
Proton Pump Inhibitors | 1 | 2017 | 526 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2020 | 6365 | 0.030 |
Why?
|
Child | 6 | 2022 | 77709 | 0.030 |
Why?
|
Preoperative Care | 2 | 2014 | 2250 | 0.030 |
Why?
|
Lymph Nodes | 2 | 2019 | 3474 | 0.020 |
Why?
|
Recurrence | 4 | 2015 | 8340 | 0.020 |
Why?
|
Digestive System | 2 | 1984 | 253 | 0.020 |
Why?
|
Body Weight | 1 | 2022 | 4669 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3616 | 0.020 |
Why?
|
Neoplasms, Second Primary | 2 | 1996 | 1061 | 0.020 |
Why?
|
Weight Loss | 1 | 2022 | 2622 | 0.020 |
Why?
|
Electrophoresis | 1 | 1990 | 240 | 0.020 |
Why?
|
Genomic Instability | 1 | 2015 | 695 | 0.020 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 1980 | 1378 | 0.020 |
Why?
|
Bone Marrow Transplantation | 2 | 1990 | 2765 | 0.020 |
Why?
|
Biomarkers, Pharmacological | 1 | 2011 | 162 | 0.020 |
Why?
|
Delayed Diagnosis | 1 | 2013 | 441 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2014 | 1878 | 0.020 |
Why?
|
Cardiac Electrophysiology | 1 | 2009 | 49 | 0.020 |
Why?
|
Esthetics | 1 | 1991 | 306 | 0.020 |
Why?
|
Double-Blind Method | 4 | 2005 | 12026 | 0.020 |
Why?
|
Heart Failure | 1 | 2013 | 10900 | 0.020 |
Why?
|
Alkylating Agents | 2 | 1986 | 139 | 0.020 |
Why?
|
Tumor Burden | 1 | 2015 | 1915 | 0.020 |
Why?
|
Mice, SCID | 1 | 2014 | 2716 | 0.020 |
Why?
|
Social Class | 1 | 2018 | 1999 | 0.020 |
Why?
|
Carmustine | 3 | 1990 | 137 | 0.020 |
Why?
|
Population Surveillance | 1 | 2019 | 2616 | 0.020 |
Why?
|
Stress, Physiological | 2 | 1974 | 1403 | 0.020 |
Why?
|
Pulmonary Wedge Pressure | 1 | 1989 | 264 | 0.020 |
Why?
|
Cost of Illness | 1 | 2018 | 1859 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9849 | 0.020 |
Why?
|
Erythropoiesis | 1 | 1972 | 705 | 0.020 |
Why?
|
Alleles | 1 | 2019 | 6933 | 0.020 |
Why?
|
Survival Analysis | 4 | 2005 | 10252 | 0.020 |
Why?
|
Polyglutamic Acid | 1 | 2007 | 44 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2004 | 16689 | 0.020 |
Why?
|
Pilot Projects | 4 | 2010 | 8324 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 1799 | 0.020 |
Why?
|
Genes, erbB-2 | 1 | 2007 | 162 | 0.020 |
Why?
|
Vincristine | 5 | 1991 | 1039 | 0.020 |
Why?
|
Body Mass Index | 2 | 2015 | 12720 | 0.020 |
Why?
|
Salvage Therapy | 1 | 1993 | 1275 | 0.020 |
Why?
|
Administration, Oral | 1 | 2014 | 3913 | 0.020 |
Why?
|
Heart | 1 | 1999 | 4467 | 0.020 |
Why?
|
Gene Amplification | 1 | 2010 | 1063 | 0.020 |
Why?
|
Fees and Charges | 1 | 1987 | 195 | 0.020 |
Why?
|
Prednisone | 6 | 1991 | 1574 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2015 | 2938 | 0.020 |
Why?
|
Technetium Tc 99m Aggregated Albumin | 1 | 1984 | 67 | 0.020 |
Why?
|
Up-Regulation | 1 | 2014 | 4217 | 0.020 |
Why?
|
Male | 17 | 2022 | 350118 | 0.020 |
Why?
|
Animals | 4 | 2014 | 168757 | 0.020 |
Why?
|
Genotype | 1 | 2019 | 12951 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2020 | 13989 | 0.010 |
Why?
|
Lung Neoplasms | 3 | 2017 | 13102 | 0.010 |
Why?
|
Liver Neoplasms | 4 | 1981 | 4253 | 0.010 |
Why?
|
Pulmonary Valve Stenosis | 1 | 1985 | 183 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2010 | 2649 | 0.010 |
Why?
|
Self Report | 1 | 2015 | 3558 | 0.010 |
Why?
|
Infusions, Parenteral | 2 | 1981 | 419 | 0.010 |
Why?
|
Metabolic Clearance Rate | 1 | 2004 | 380 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5137 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2023 | 25625 | 0.010 |
Why?
|
Phosphatidylethanolamines | 2 | 1974 | 134 | 0.010 |
Why?
|
Boston | 2 | 2005 | 9313 | 0.010 |
Why?
|
Phenotype | 1 | 2020 | 16365 | 0.010 |
Why?
|
Half-Life | 1 | 2004 | 661 | 0.010 |
Why?
|
Carcinoid Heart Disease | 1 | 1982 | 10 | 0.010 |
Why?
|
Malignant Carcinoid Syndrome | 1 | 1982 | 31 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2014 | 3610 | 0.010 |
Why?
|
Neoplastic Cells, Circulating | 1 | 1989 | 934 | 0.010 |
Why?
|
Gelatin Sponge, Absorbable | 1 | 1981 | 60 | 0.010 |
Why?
|
Mediastinal Neoplasms | 1 | 1985 | 423 | 0.010 |
Why?
|
Emetics | 1 | 1980 | 9 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2014 | 3597 | 0.010 |
Why?
|
Pharmacology, Clinical | 1 | 1981 | 21 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15540 | 0.010 |
Why?
|
Massachusetts | 1 | 2014 | 8663 | 0.010 |
Why?
|
Erythrocyte Transfusion | 1 | 2005 | 565 | 0.010 |
Why?
|
Drug Evaluation | 3 | 1991 | 647 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2014 | 3229 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2016 | 6234 | 0.010 |
Why?
|
Adenocarcinoma | 2 | 1989 | 6364 | 0.010 |
Why?
|
Statistics as Topic | 1 | 1987 | 2373 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2013 | 3022 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2019 | 15519 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2013 | 3086 | 0.010 |
Why?
|
Area Under Curve | 1 | 2004 | 1654 | 0.010 |
Why?
|
Patient Admission | 1 | 1987 | 1380 | 0.010 |
Why?
|
Procarbazine | 3 | 1985 | 181 | 0.010 |
Why?
|
Mechlorethamine | 3 | 1985 | 136 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2015 | 8428 | 0.010 |
Why?
|
Lymphography | 1 | 1979 | 201 | 0.010 |
Why?
|
North America | 1 | 2002 | 1249 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2014 | 10481 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2014 | 19229 | 0.010 |
Why?
|
Duodenum | 1 | 1981 | 483 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1998 | 5686 | 0.010 |
Why?
|
Surgery, Plastic | 1 | 1985 | 624 | 0.010 |
Why?
|
Drug Therapy, Combination | 4 | 1983 | 6489 | 0.010 |
Why?
|
Conditioning, Classical | 1 | 1980 | 366 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2012 | 4245 | 0.010 |
Why?
|
Adenoma, Islet Cell | 1 | 1977 | 82 | 0.010 |
Why?
|
Stomach | 1 | 1981 | 697 | 0.010 |
Why?
|
Physicians | 1 | 2015 | 4567 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2009 | 3670 | 0.010 |
Why?
|
Ovarian Neoplasms | 2 | 1986 | 4838 | 0.010 |
Why?
|
Laparotomy | 2 | 1995 | 473 | 0.010 |
Why?
|
Blood Transfusion | 2 | 1974 | 1301 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1998 | 876 | 0.010 |
Why?
|
Respiratory System | 1 | 1979 | 557 | 0.010 |
Why?
|
Ambulatory Care | 1 | 1987 | 2708 | 0.010 |
Why?
|
Radiation Dosage | 1 | 2004 | 1928 | 0.010 |
Why?
|
Osmotic Fragility | 1 | 1974 | 37 | 0.010 |
Why?
|
Edema | 1 | 1999 | 789 | 0.010 |
Why?
|
Phosphorus Radioisotopes | 1 | 1974 | 104 | 0.010 |
Why?
|
Remission Induction | 2 | 1991 | 2386 | 0.010 |
Why?
|
Lung | 2 | 1984 | 9856 | 0.010 |
Why?
|
Erythrocytes | 2 | 1974 | 2455 | 0.010 |
Why?
|
Cell Membrane | 2 | 1974 | 3748 | 0.010 |
Why?
|
Carbon Radioisotopes | 1 | 1974 | 577 | 0.010 |
Why?
|
Abdomen | 1 | 1979 | 1118 | 0.010 |
Why?
|
Echocardiography | 2 | 1985 | 5102 | 0.010 |
Why?
|
Splenectomy | 1 | 1974 | 395 | 0.010 |
Why?
|
Isotope Labeling | 1 | 1974 | 406 | 0.010 |
Why?
|
Hemolysis | 1 | 1974 | 420 | 0.010 |
Why?
|
Child, Preschool | 4 | 1996 | 41006 | 0.010 |
Why?
|
Lymphocytes | 1 | 1980 | 2617 | 0.010 |
Why?
|
Phosphorus Isotopes | 1 | 1972 | 126 | 0.010 |
Why?
|
Chromatography, Thin Layer | 1 | 1972 | 223 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 1991 | 5221 | 0.010 |
Why?
|
Embolization, Therapeutic | 1 | 1981 | 1392 | 0.010 |
Why?
|
Hemorrhage | 2 | 1974 | 3461 | 0.010 |
Why?
|
Carbon Isotopes | 1 | 1972 | 467 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1974 | 2645 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2007 | 15076 | 0.010 |
Why?
|
Cytoplasm | 1 | 1974 | 1539 | 0.010 |
Why?
|
Bone Marrow | 1 | 1979 | 2948 | 0.010 |
Why?
|
Glycine | 1 | 1972 | 671 | 0.010 |
Why?
|
Bone and Bones | 1 | 1979 | 2575 | 0.010 |
Why?
|
Hemoglobins | 1 | 1974 | 1534 | 0.010 |
Why?
|
Etoposide | 1 | 1990 | 641 | 0.010 |
Why?
|
Cardiac Tamponade | 1 | 1989 | 173 | 0.000 |
Why?
|
Rats | 2 | 1974 | 24260 | 0.000 |
Why?
|
Liver | 2 | 1979 | 7474 | 0.000 |
Why?
|
United States | 1 | 2014 | 69872 | 0.000 |
Why?
|
Receptors, Steroid | 1 | 1987 | 155 | 0.000 |
Why?
|
Skin | 1 | 1979 | 4364 | 0.000 |
Why?
|
Thiotepa | 1 | 1985 | 66 | 0.000 |
Why?
|
Algorithms | 1 | 2005 | 13881 | 0.000 |
Why?
|
Liver Circulation | 1 | 1984 | 164 | 0.000 |
Why?
|
Microcirculation | 1 | 1989 | 1286 | 0.000 |
Why?
|
Radiotherapy, High-Energy | 1 | 1985 | 228 | 0.000 |
Why?
|
Risk | 1 | 1996 | 9687 | 0.000 |
Why?
|
Melphalan | 1 | 1985 | 431 | 0.000 |
Why?
|
Heart Murmurs | 1 | 1982 | 94 | 0.000 |
Why?
|
Bleomycin | 1 | 1983 | 512 | 0.000 |
Why?
|
Hysterectomy | 1 | 1986 | 927 | 0.000 |
Why?
|
Pulmonary Valve Insufficiency | 1 | 1982 | 151 | 0.000 |
Why?
|
Perfusion | 1 | 1984 | 1360 | 0.000 |
Why?
|
Colloids | 1 | 1980 | 136 | 0.000 |
Why?
|
Dacarbazine | 1 | 1983 | 566 | 0.000 |
Why?
|
Technetium | 1 | 1980 | 334 | 0.000 |
Why?
|
Sulfur | 1 | 1980 | 166 | 0.000 |
Why?
|
Nitrosourea Compounds | 1 | 1978 | 32 | 0.000 |
Why?
|
Physical Examination | 1 | 1985 | 1237 | 0.000 |
Why?
|
Hepatic Veins | 1 | 1978 | 112 | 0.000 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 1982 | 349 | 0.000 |
Why?
|
Tolbutamide | 1 | 1977 | 23 | 0.000 |
Why?
|
Diazoxide | 1 | 1977 | 57 | 0.000 |
Why?
|
Reoperation | 1 | 1986 | 4201 | 0.000 |
Why?
|
Streptozocin | 1 | 1977 | 196 | 0.000 |
Why?
|
Serum Albumin | 1 | 1980 | 676 | 0.000 |
Why?
|
Radionuclide Imaging | 1 | 1980 | 2031 | 0.000 |
Why?
|
Tissue Distribution | 1 | 1980 | 2327 | 0.000 |
Why?
|
Leucine | 1 | 1977 | 561 | 0.000 |
Why?
|
Glucagon | 1 | 1977 | 533 | 0.000 |
Why?
|
Veins | 1 | 1978 | 770 | 0.000 |
Why?
|
Mammography | 1 | 1985 | 2476 | 0.000 |
Why?
|
Gastrointestinal Diseases | 1 | 1981 | 1170 | 0.000 |
Why?
|
Infant | 1 | 1995 | 35136 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 1995 | 15165 | 0.000 |
Why?
|
Blood Glucose | 1 | 1977 | 6256 | 0.000 |
Why?
|
Insulin | 1 | 1977 | 6580 | 0.000 |
Why?
|